pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Antibody-Drug Conjugate (ADC) · news · pharmadog
← back to Antibody-Drug Conjugate (ADC)
News · Antibody-Drug Conjugate (ADC)
230
stories
24d
GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial
fiercebiotech
24d
STAT+: Roche gets a lung cancer win with its KRAS drug divarasib
stat
24d
STAT+: HHS relaxes security, transparency rules for health record software used by hospitals
stat
24d
STAT+: GSK sees its return to cancer start to pay off
stat
24d
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
biopharma dive
24d
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
biospace
24d
STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
stat
24d
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
biospace
24d
#ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancer
endpoints
24d
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
biospace
25d
BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results
endpoints
25d
Novel protein and peptide therapeutics
biopharma dive
25d
BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
fiercebiotech
26d
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
endpoints
27d
ESMO: AstraZeneca exec insists phase 3 ADC data ‘robust’ enough for regulators despite PFS miss
fiercebiotech
27d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
27d
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
biospace
28d
ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
fiercebiotech
29d
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
biospace
29d
ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up
fiercebiotech
Oct 21, 26
The 6 biggest crossover rounds in biopharma history
biospace
Oct 20, 26
STAT+: Roche continues to look to China for new drugs
stat
Oct 20, 26
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
biopharma dive
Oct 20, 26
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push
biospace
Oct 20, 26
Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
biospace
Oct 20, 26
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
fiercebiotech
Oct 19, 26
Roche returns to Hansoh with broad $15B ADC deal
biospace
Oct 19, 26
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
biopharma dive
Oct 19, 26
Extractables in single-use systems used in ADC manufacturing
biopharma dive
Oct 19, 26
Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact
fiercebiotech
← prev
page 2 of 8
next →